After the improvement is achieved,the patient is transferred to a maintenance dose of 50-100 mg(Table 1 of the preparation Anafranil® CP or 2-4 tablets of the preparation Anafranil®).
Either way, creatine loading is, essentially, taking large amounts(10-20+ grams) for the first 5-7 days,and then continuing to take the normal“maintenance dose”(typically 5g) each day.
維持用量は1ペッサリーです。
The maintenance dose is one pessary inserted twice per week.
推奨される維持用量は80ミリグラム。
The recommended maintenance dose is 80 mg.
維持用量は1〜8日で到達した。
Maintenance dose reached in 1 to 8 days.
維持用量は50-200mg/日である。
The maintenance dose is 50-200 mg/ day.
初期および維持用量は20mg/日である。
Initial and maintenance doses of 20 mg/ day.
治療の1年後、患者は、天然製剤の維持用量に移された。
After a year of treatment the patient was transferred to maintenance doses of natural preparations.
患者の症状の改善が一旦生じると、維持用量が必要であれば投与される。
Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary.
維持用量は1日あたり1000-2000mgであり、最大1日用量は2500mgである。
The maintenance dose is 1000-2000 mg per day,the maximum daily dose is 2500 mg.
維持用量-疾患の臨床症状の消失した後-50日Mg又は週に1〜2回。
After the disappearance of clinical manifestations of the disease- in supporting the dose- 50 mg a day or 1-2 times a week.
維持用量は、個別に調整されています,忍容性に応じて、,治療効果および患者の状態。
The maintenance dose is adjusted individually, depending on tolerability, therapeutic effect and the condition of the patient.
治療は継続され(1年まで)、その後、治療計画に従って、患者は真菌製剤の維持用量を提供される。
Treatment continues(up to a year), and then, according to the treatment plan,the patient will be offered a maintenance dose of fungal preparations.
An additional maintenance dose of GcMAF can be necessary for patients, so that they remain symptom- free and that immune system sufficient regeneration time.
In applying the drug should be noted that the therapeutic effect isnot earlier than after 1-3 weeks of treatment, the maintenance dose should be taken at least 3 months.
Be wary appoint older, weakened and malnourished patients and patients with adrenal andpituitary insufficiency avoid hypoglycemic reactions of initial and maintenance doses should not be high.
In a situation where the patient has an endocrine-type enzymopathy, the only pathogenetically justified treatmentis hormonal therapy in a sustained course in a maintenance dosage.
日本語
中文
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt